Report a data issue, formatting problem, or request follow-up. Our team responds within one business day.
Be the first to review this report.
L (+) Ergothioneine is a naturally occurring sulfur containing derivative of L histidine with the molecular formula C9H15N3O2S and a molecular mass of 229.30 g/mol. Its molecular structure contains a trimethylated histidine backbone and a sulfur substituted imidazole ring, forming an amino acid betaine with a permanent zwitterionic character. The molecule exists in equilibrium between thiol and thione tautomers. At physiological pH the thione form predominates, which substantially limits spontaneous oxidation and gives ergothioneine greater chemical stability than many conventional low molecular weight thiols. This thione chemistry also permits redox reactions and transition metal coordination while retaining high aqueous solubility. High purity commercial material is typically supplied as a white crystalline powder. The synthetic material assessed by the European Food Safety Authority specifies chemical purity of at least 99.5 percent by HPLC and positive optical rotation consistent with the naturally occurring L configuration. Natural ergothioneine biosynthesis occurs in selected fungi and bacteria through histidine derived sulfur incorporation pathways. Mushrooms contain particularly high concentrations, while lower concentrations occur in beans, cereals, animal tissues and other foods through biological uptake and food chain transfer. Humans do not possess a known endogenous biosynthetic pathway for ergothioneine and obtain it from dietary sources. Absorption and tissue retention are strongly associated with the SLC22A4 transporter, commonly termed OCTN1 or the ergothioneine transporter, which mediates intestinal uptake, cellular accumulation and renal reabsorption. Ergothioneine can consequently accumulate in erythrocytes and several tissues despite relatively low dietary concentrations. Its thione dominated chemistry gives the molecule resistance to autoxidation and enables reactions with reactive oxygen and nitrogen species and coordination with selected metal ions. These physicochemical properties underpin its use as a functional ingredient, while its precise physiological roles in humans remain an active area of biochemical research. Industrial L (+) Ergothioneine is manufactured principally by microbial fermentation, enzyme catalyzed synthesis and chemical synthesis. Commercial fermentation routes use engineered microorganisms carrying ergothioneine biosynthetic enzymes, with current FDA GRAS records documenting production using engineered Escherichia coli strains. Chemical production has also been established commercially and was the manufacturing basis of the synthetic material evaluated by EFSA. Enzyme catalyzed routes convert histidine derived precursors through selective sulfur incorporation reactions and are currently used by commercial ingredient manufacturers. These technologies produce chemically equivalent L ergothioneine when stereochemical configuration, molecular identity, purity and impurity specifications are controlled. Commercial material is used in dietary supplements, foods and beverages, cosmetics and personal care formulations, with food use subject to jurisdiction specific regulatory requirements. The European Union currently lists L ergothioneine as an authorised novel food for specified food categories and food supplements.
According to APO Research, Inc, the global L (+) Ergothioneine market was valued at USD 68.53 million in 2025 and is expected to reach USD 84.17 million in 2026 and USD 191.86 million by 2032, representing a CAGR of 14.72% from 2026 to 2032. Global sales volume is estimated at 25.86 t in 2025 and 33.40 t in 2026, reaching 107.79 t in 2032, equivalent to a volume CAGR of 21.56%. The weighted ex factory net price is estimated at USD 2,650.00 per kg in 2025, USD 2,520.00 per kg in 2026 and USD 1,780.00 per kg in 2032, corresponding to an average annual price decline of 5.63% during 2026 to 2032. Effective manufacturing capacity is estimated at 72.50 t in 2025, 92.01 t in 2026 and 189.97 t in 2032, while utilization increases from 35.67% to 36.30% and 56.74%, respectively. The value expansion therefore comes primarily from higher physical consumption, rising utilization and broader downstream formulation volumes as fermentation productivity and purification economics reduce unit cost.
China is expected to contribute the largest manufacturing increment through GeneIII Biotechnology, Chuanning Biotechnology, Shanghai EGT Synbio, Readline Biotech, SIYOMICRO, Bloomage Biotech, Abiochem and other commercial producers. GeneIII reports monthly L (+) Ergothioneine capacity of 3.00 to 5.00 t, equivalent to 36.00 to 60.00 t on an annualized basis, with product purity reaching 99.99%. This disclosed capacity alone exceeds the audited 2026 global sales volume of 33.40 t and provides a direct physical explanation for the relatively low industry utilization rate. SIYOMICRO has reported stable production scale up in a 100.00 t fermenter, while Readline has commissioned two hundred tonne class shared active ingredient production lines in Zhuhai with commercial scale production of ergothioneine. Chuanning exceeded its 11.00 g/L fermentation titer objective and annual production target in 2025. Bloomage commercially produces MitoEGT through one step biosynthesis, and Shanghai EGT Synbio has established commercial biological production of Dr.Ergo. The current FDA GRAS inventory contains four ergothioneine notices. Blue California, Shanghai EGT Synbio and GeneIII have received FDA no questions letters. Abiochem remains under review.
Fermentation is expected to account for the largest incremental production volume through 2032 as strain productivity, fermentation titer, reactor scale, downstream recovery and crystallization yield improve. Enzymatic synthesis and chemical synthesis remain relevant for selected manufacturing configurations and purity specifications. Dietary supplements are expected to remain the largest application by value, followed by food and beverages and cosmetics and personal care, with pet nutrition representing a smaller commercial application. Regulatory inclusion levels provide a useful physical demand anchor. The European Union permits up to 30.00 mg per day in food supplements for the general population, 25.00 mg per kg in alcohol free beverages and milk based drinks, 40.00 mg per kg in fresh milk products, 200.00 mg per kg in cereal bars and 250.00 mg per kg in chocolate confectionery. At 30.00 mg per day, 1.00 t of L (+) Ergothioneine corresponds to approximately 33.33 million supplement consumption days. At 25.00 mg per kg, 1.00 t can theoretically supply 40,000.00 t of beverage at the permitted maximum inclusion level. These low unit dosages allow large downstream finished product volumes to absorb relatively modest ingredient tonnage, while continued price reductions materially enlarge the addressable formulation base. Commercial demand is recurrent because L (+) Ergothioneine is consumed within finished formulations and replenished with continuing supplement, food, beverage, cosmetic and pet nutrition production.
This report provides an overview of the global L-(+)-Ergothioneine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of L-(+)-Ergothioneine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents L-(+)-Ergothioneine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the L-(+)-Ergothioneine market size, projected growth trends, production technologies, key applications, and end-use industries.
Chapter 1: Provides an overview of the L-(+)-Ergothioneine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global L-(+)-Ergothioneine industry.
Chapter 3: Detailed analysis of L-(+)-Ergothioneine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of L-(+)-Ergothioneine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of L-(+)-Ergothioneine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
You may also be interested in
